Recurrent Subcutaneous Sweet's Disease in a Myelofibrosis Patient Treated with Ruxolitinib before Allogeneic Stem Cell Transplantation
| Autor: | Kenjiro Kamezaki, Kensuke Sasaki, Masutaka Furue, Konosuke Nagae, Hiromi Iwasaki, Koji Kato, Yasuo Mori, Teppei Sakoda, Toshihiro Miyamoto, Koichi Akashi, Etsuko Yonemitsu, Goichi Yoshimoto, Yoko Kanamitsu, Katsuto Takenaka |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Oncology Male medicine.medical_specialty Ruxolitinib ruxolitinib medicine.medical_treatment Case Report myelofibrosis Disease Hematopoietic stem cell transplantation Sweet's disease stem cell transplantation 03 medical and health sciences 0302 clinical medicine Internal medicine Nitriles Internal Medicine medicine Humans Myelofibrosis Glucocorticoids Aged business.industry Clinical course Hematopoietic Stem Cell Transplantation General Medicine medicine.disease Sweet Syndrome Transplantation 030104 developmental biology Pyrimidines Primary Myelofibrosis 030220 oncology & carcinogenesis Chronic Disease Pyrazoles subcutaneous Stem cell business medicine.drug |
| Zdroj: | Internal Medicine |
| ISSN: | 1349-7235 |
| Popis: | Allogeneic hematopoietic stem cell transplantation (allo-SCT) has a curative potential for myelofibrosis (MF) patients; however, its association with a high therapy-related mortality (TRM) remains a big obstacle that needs to be overcome. Ruxolitinib (RUXO), a novel JAK1/2 inhibitor, can be used as a bridging therapy until allo-SCT can be performed to reduce TRM. We herein report a RUXO-treated MF patient who developed recurrent subcutaneous Sweet's disease (SSD) that was successfully treated by the administration of systemic glucocorticoids. We performed allo-SCT as previously scheduled, resulting in a good clinical course without deterioration of SSD. RUXO administration, as well as MF itself, might therefore sometimes cause this rare non-infectious event. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|